The company's low P/E is due to its outlook for shrinking earnings. Investors believe the potential for earnings improvement doesn't justify a higher P/E, limiting the chances of a strong share price rise soon.
Quanex Building Products is undervalued, presenting a good opportunity to increase holdings. The company's future outlook isn't fully reflected in the current share price, making it a good time to invest.
The large scale share sell-off from the Independent Lead Director around current prices raises concern. Lack of recent insider purchases despite significant ownership increases caution towards the company.
Gainers: •$Okta(OKTA.US)$+15.8% (In reaction to earnings) •$StoneCo(STNE.US)$+12.9% (In reaction to earnings) •$Turning Point Therapeutics(TPTX.US)$+116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025) •$Amylyx Pharmaceuticals(AMLX.US)$+24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
lightfoot :
This will be a solid stock and add it to your portfolio. I see NX a growth stock. financials are sound. Sales now. Beware of Biden recession A time to buy like the Mortgage bubble in 2008-9.
Quanex Building Products股票讨论区
专栏Today's Pre-Market Stock Movers: AVGO, RKLB, LULU, XOM and More
In reaction to earnings/guidance:
• $HashiCorp(HCP.US)$ +16.8%,$Lululemon Athletica(LULU.US)$ +9.7%,$PagerDuty(PD.US)$ +5%,$nCino(NCNO.US)$ +3.8% (also Bank Operating System selected by Rabobank Australia and New Zealand),$博通(AVGO.US)$ +2.1%
Other news:
• $Ooma(OOMA.US)$ +3.5% (acquires Junction Networks also reports earnings)
• $Momentus(MNTS.US)$ +3.5% (files for $200 mln mixed securities shelf offering)
• $Humacyte(HUMA.US)$ +2.9% (fi...
Quanex Building Products(NX) 是2008年以13美元上市的美国公司,当前价格23.98,14年来平均回报率为4.5%,比较平淡。
5年来毛利率在22%上下波动,净资产收益率则是从4.8上升到了14.7%,利润水平在板块内偏低。
5年来营收前4年变化不大,2021年大幅增长25.9%,营业利润则是近三年连续增长,2021年达到46.6%,净利润2019年大幅亏损,2020扭亏并连续两年增长。2019年亏损是由于当年有7,460万的资本性资产减值。
2022前两季度营收营业利润和净利润分别增长17.9%,46.4%,68.6%。
2021年利润表显示利息费用逐年递减,2021年仅占营业利润的3%,负担很低。
5年来资产负债率从47.4%下降到41.1%,应收款项和存货比例都很低,但是2021年累计增长了5130万,远超净利润增长的1848万,利润增长比较虚。
商誉及其他无形资产2.17亿,占净资产4.2亿的52%。长期借款7,571.4万,比例不算高。
5年来经营净额大比例超过投资净额,...
专栏Today's pre-market stock movers: TSLA, CHGG, OKTA, TPTX and more
• $Okta(OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo(STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics(TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals(AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
暂无评论